A pivotal role for pneumolysin in the immunopathogenesis, treatment and prevention of pneumococcal disease

South African Medical Journal

Volumn 97, Issue 11 III, 2007, Pages 1141-1145

  Feldman, Charles ^a   Anderson, Ronald ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; AMOXICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BACTERIUM ANTIBODY; BETA LACTAM ANTIBIOTIC; BINDING PROTEIN; CEFTRIAXONE; CHOLINE BINDING PROTEIN A; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; CORTICOSTEROID; ERYTHROMYCIN; INACTIVATED VACCINE; MACROLIDE; MEMBRANE PROTEIN; MOXIFLOXACIN; PNEUMOCOCCAL HISTIDINE TRIAD PROTEIN B; PNEUMOCOCCAL HISTIDINE TRIAD PROTEIN E; PNEUMOCOCCAL SURFACE ADHESIN A; PNEUMOCOCCAL SURFACE PROTEIN A; PNEUMOCOCCAL SURFACE PROTEIN B; PNEUMOCOCCAL SURFACE PROTEIN C; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; POLYSACCHARIDE; TELITHROMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL VIRULENCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; CYTOTOXICITY; HOST RESISTANCE; HUMAN; IMMUNOGENICITY; IMMUNOPATHOGENESIS; INFLAMMATION; LOBAR PNEUMONIA; LOW DRUG DOSE; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOLYSINS; VIRULENCE;

EID: 37349115897     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Spreer A, Lis A, Gerber J, et al. Differences in clinical manifestations of Streptococcus pneumoniae infection are not correlated with in vitro production and release of the virulence factors pneumolysin and lipoteichoic and teichoic acids. J Clin Microbiol 2004; 42: 3342-3345.
2. Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. N Engl J Med 2000; 342: 681-689.
3. Cockeran R, Anderson R, Feldman C. The role of pneumolysin in the pathogenesis of Streptococcus pneumoniae infection. Curr Opin Infect Dis 2002; 15: 235-239.
4. Cockeran R, Anderson R, Feldman C. Pneumolysin in the immunopathogenesis and treatment of pneumococcal disease. Expert Rev Anti Infect Ther 2003; 1: 231-239.
5. Cockeran R, Anderson R, Feldman C. Pneumolysin as a vaccine and drug target in the prevention and treatment of invasive pneumococcal disease. Arch Immunol Ther Exp 2005; 53: 189-198.
6. Tuomanen EI. Pathogenesis of pneumococcal inflammation: otitis media. Vaccine 2001; 19: S38-S40.
7. Jedrzejas MJ. Pneumococcal virulence factors: structure and function. Microbiol Molec Biol Rev 2001; 65: 187-207.
8. Gillespie SH, Balakrishnan I. Pathogenesis of pneumococcal infection. J Med Microbiol 2000; 49: 1057-1067.
9. Mitchell TJ. Virulence factors and the pathogenesis of disease caused by Streptococcus pneumoniae. Res Microbiol 2000; 151: 413-419.
10. Bogaert D, de Groot R, Hermans PWM. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004; 4: 144-154.
11. Malley R, Henneke P, Morse SC, et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA 2003; 100: 1966-1971.
12. Fickl H, Cockeran R, Steel HC, et al. Pneumolysin-mediated activation of NF B in human neutrophils is antagonized by docosahexaenoic acid. Clin Exp Immunol 2005; 140: 274-281.
13. Van Rossum AM, Lysenko ES, Weisner JN. Host and bacterial factors contributing to the clearance of colonization of Streptococcus pneumoniae in a murine model. Infect Immun 2005; 73: 7718-7726.
14. Ratner AJ, Hippe KR, Aguilar JL, et al. Epithelial cells are sensitive detectors of bacterial pore-forming toxins. J Biol Chem 2006; 281: 12994-12998.
15. Garcia-Suarez M del M, Florez N, Astudillo A, et al. The role of pneumolysin in mediating lung damage in a lethal pneumococcal pneumonia marine model. Respir Rex 2007; 8: 3.
16. Witzenrath M, Gutbier B, Hocke AC, et al. Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia. Crit Care Med 2006; 34: 1947-1954.
17. Hirst RA, Mohammed BJ, Mitchell TJ, et al. Streptococcus pneumoniac-induced inhibition of rat ependymal cilia is attenuated by antipneumolysin antibody. Infect Immun 2004; 72: 6694-6698.
18. Zhang Q, Bernatoniene J, Bagrade L, et al. Regulation of production of mucosal antibody to pneumococcal protein antigens by T-cell-derived gamma interferon and interleukin-10 in children. Infect Immun 2006; 74: 4735-4743.
19. Cairns B, Maile R, Barnes CM, et al. Increased Toll-like receptor 4 expression on T cells may be a mechanism for enhanced T cell response late after burn injury. J Trauma 2006; 61: 293-298.
20. Musher DM, Phan HM, Baughn RE. Protection against bacteremic pneumococcal infection by antibody to pneumolysin. J Infect Dis 2001; 183: 827-830.
21. Huo Z, Spencer O, Miles J, et al. Antibody response to pneumolysin and to pneumococcal capsular polysaccharide in healthy individuals and Streptococcus pneumoniae infected patients. Vaccine 2004; 22: 1157-1161.
22. Goldblatt D, Hussain M, Andrews N, et al. Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. J Infect Dis 2005; 192: 387-393.
23. Holmlund E, Quiambao B, Ollgren J, et al. Development of natural antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A and pneumolysin in Filipino pregnant women and their infants in relation to pneumococcal carriage. Vaccine 2006; 24: 57-65.
24. Zhang Q, Bernatoniene J, Bagrade L, et al. Serum and mucosal antibody responses to pneumococcal protein antigens: relationships with carriage status. Eur Immunol 2006; 36: 46-37.
25. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007; 297: 1794-1792.
26. Tai S. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit Rev Microbiol 2006; 32: 139-153.
27. Lee C-J, Wang TR, Frasch CE. Immunogenicity in mice of pneumococcal glycoconjugate vaccines using pneumococcal protein carriers. Vaccine 2001; 19: 3216-3225.
28. Kirkham LA, Kerr AR, Douce GR, et al. Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines. Infect Immun 2006; 74: 586-593.
29. Ogunniyi AD, Grabowicz M, Briles DE, et al. Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun 2007; 75: 350-357.
30. Feldman C, Anderson R. Controversies in the treatment of pneumococcal community-acquired pneumonia. Future Med 2006; 1: 271-281.
31. Anderson R, Steel HC, Cockeran R, et al. Clarithromycin alone and in combination with ceftriaxone inhibits the production of pneumolysin by both macrolide-susceptible and macrolide-resistant strains of Streptococcus pneumoniae. J Antimicrob Chemother 2007; 59: 224-229.
32. Fukuda Y, Yanagihara K, Higashiyama Y, et al. Effects of maccolides against pneumolysin of macrolide-resistant Streptococcus pneumoniae. Eur Respir J 2006; 27: 1020-1025.
33. Anderson R, Steel HC, Cockeran R, et al. Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin. J Antimicrob Chemother 2007; Epub ahead of print: doi:101093/jac/dlem 338.